Revolution Medicines, Inc. RVMD · Stock Open Revolution Medicines, Inc. in new tab
Revolution Medicines, Inc. Analysis (RVMD)
Is Revolution Medicines, Inc. a good investment? Revolution Medicines, Inc. (RVMD) is currently trading at 182.45 USD. Market analysts have a consensus price target of 207.00 USD. This suggests a potential upside from current levels.
Earnings Schedule: Revolution Medicines, Inc. is expected to release its next earnings report on Aug. 5, 2026. The market consensus estimate for Forward EPS is -5.80.
Investor FAQ
Does Revolution Medicines, Inc. pay a dividend?
No, it does not currently pay a dividend.
What asset class is Revolution Medicines, Inc.?
Revolution Medicines, Inc. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.
When is the next earnings date?
The next earnings date is projected to be Aug. 5, 2026. The company currently has a trailing EPS of -7.10.
Company Profile
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291) which is in early clinical development for the treatment of solid tumors, and zoldonrasib G12D (RMC-9805), which are in phase 3 registrational trial evaluating the combination of daraxonrasib with zoldonrasib in patients with 1L PDAC; and development candidates comprise RMC-5127 (G12V) which is in clinical trial, RMC-0708 (Q61H), that is in clinical trial; and RMC-8839 (G13C). Revolution Medicines, Inc. was incorporated in 2014 and is headquartered in Redwood City, California.
Community Discussion